# TICAROS

Source: https://onco.cc/companies/ticaros/  
OnCo record `ticaros` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TICAROS is a Korean company making CAR-T cell therapy, in which a patient's own immune cells are engineered to recognise and kill cancer cells. Its first product, TC011, targets CD19 and is being tested in B-cell lymphomas that have come back or stopped responding.

## Summary

TICAROS Co., Ltd., based in Seongdong-gu, Seoul, develops gene-modified T cell therapies. Its CLIP-CAR (Clamping-based Immunological Synapse Potentiating CAR) platform is designed to improve CAR-T efficacy, and it also lists a Converter CAR platform. TC011, an autologous anti-CD19 CAR-T, is in a multicentre phase 1/2 study in relapsed or refractory large B-cell non-Hodgkin lymphoma (NCT07473167, registered in March 2026 with a recorded start in August 2023) and a phase 2 study in relapsed or refractory follicular lymphoma (NCT07360288). The company reports receiving dual A ratings in the technology assessment for a KOSDAQ listing. Its first registered cancer trial, NCT07360288, was posted on ClinicalTrials.gov in January 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: TiCARos
- HQ: Seoul
- Type: cell-therapy
- Website: https://www.ticaros.com/

## Notes

- Read on 29 October 2026: ticaros.com English home page (address, platform names and a news headline about the KOSDAQ technology assessment). The site did not state TC011's target; CD19 comes from the ClinicalTrials.gov record NCT07473167.
- Founding year not stated on the company website (only a 2020 copyright line). Listing status and financing were not confirmed; stage is a judgement.
- The phase 1/2 record lists a start date in 2023 although it was posted in 2026; Korean-registry history was not checked.

## Sources

- Official website: https://www.ticaros.com/
- ClinicalTrials.gov: phase 2 trial of TC011 in follicular lymphoma (NCT07360288): https://clinicaltrials.gov/study/NCT07360288

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- trials: [Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients](https://onco.cc/trials/nct07473167/)

---
JSON: https://onco.cc/api/v1/entities/ticaros.json